Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tie2/VEGF bispecific antibody - UNITY Biotechnology

Next Previous
X
Search
Drug Profile

Tie2/VEGF bispecific antibody - UNITY Biotechnology

Alternative Names: Tie2-VEGF bispecific antibody - UNITY Biotechnology

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UNITY Biotechnology
  • Class Antibodies; Eye disorder therapies
  • Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factor A modulators; Vascular endothelial growth factor B modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy

Most Recent Events

  • 26 Apr 2022 UNITY Biotechnology expects to designate an advanced candidate by mid-2022 .
  • 26 Apr 2022 UNITY Biotechnology plans to initiate IND-enabling studies, in the second half of 2023
  • 26 Apr 2022 UNITY Biotechnology plans to initiate pilot preclinical toxicology experiments to support nomination of a development candidate

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top